PAZOPANIB Efficacy and Tolerance in Desmoids Tumors
Status:
Completed
Trial end date:
2019-09-01
Target enrollment:
Participant gender:
Summary
Desmoids tumors are benign soft tissues tumors characterized by aggressiveness and potential
local recurrence. There is a female predominance with a sex ratio of 2/1 and median age at
diagnosis is about 30 years.
Only a complete surgical excision is recommended in desmoids tumors. Some forms of desmoid
tumors are recurrent and/or symptomatic and are not accessible to a conservative surgical
treatment. In these clinical situations, only a medical treatment may achieve tumor control
and quality of life maintenance. Place of systemic treatments in the management of desmoids
tumors is poorly evaluated. Regarding chemotherapy, methotrexate and vinblastine protocol is
actually the best evaluated combination, which allowed observing objective response rate
between 40 and 75%. Toxicity was mainly marked by the risk of haematological toxicity.
Pazopanib is an inhibitor of multi-target tyrosine kinase, in oral form, with selective type
receptors -1, -2 and -3 of VEGF receptors on the PDGFA and B, and c-Kit. It is currently
under clinical development in humans in the treatment of several tumor types.